R1+New+and+emerging+treatments+in+severe+asthma.pdf (435.81 kB)
Download file

New and emerging drug treatments for severe asthma

Download (435.81 kB)
journal contribution
posted on 27.03.2019, 13:13 by S Diver, RJ Russell, CE Brightling
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people world-wide. In 5%-10% of cases, it is severe, with disproportionate healthcare resource utilization including costs associated with frequent exacerbations and the long-term health effects of systemic steroids. Characterization of inflammatory pathways in severe asthma has led to the development of targeted biological and small molecule therapies which aim to achieve disease control while minimizing corticosteroid-associated morbidity. Herein, we review currently licensed agents and those in development, and speculate how drug therapy for severe asthma might evolve and impact on clinical outcomes in the near future.

Funding

National Institute for Health Research Leicester Biomedical Research Centre, UK

History

Citation

Clin Exp Allergy, 2018, 48 (3), pp. 241-252

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

AM (Accepted Manuscript)

Published in

Clin Exp Allergy

Publisher

Wiley

eissn

1365-2222

Copyright date

2018

Available date

27/03/2019

Publisher version

https://onlinelibrary.wiley.com/doi/full/10.1111/cea.13086

Language

en

Usage metrics

Categories

Keywords

Exports